

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property  
Organization  
International Bureau

(43) International Publication Date  
27 June 2024 (27.06.2024)



(10) International Publication Number  
**WO 2024/138185 A1**

(51) International Patent Classification:

A61K 31/4439 (2006.01) A61P 11/00 (2006.01)  
A61K 31/00 (2006.01) C07D 401/00 (2006.01)  
A61K 31/4192 (2006.01)

(21) International Application Number:

PCT/US2023/085799

(22) International Filing Date:

22 December 2023 (22.12.2023)

(25) Filing Language:

English

(26) Publication Language:

English

(30) Priority Data:

63/476,995 23 December 2022 (23.12.2022) US  
63/519,703 15 August 2023 (15.08.2023) US

(71) Applicant: **BRISTOL-MYERS SQUIBB COMPANY**  
[US/US]; Route 206 and Province Line Road, Princeton,  
New Jersey 08543 (US).

(72) Inventors: **FISCHER, Aryeh**; c/o Bristol-Myers Squibb  
Company, Route 206 and Province Line Road, Princeton,  
New Jersey 08543 (US). **GREENBERG, Steven**; c/o Bris-  
tol-Myers Squibb Company, Route 206 and Province Line  
Road, Princeton, New Jersey 08543 (US). **PARKAR, Ash-  
faq A.**; c/o Bristol-Myers Squibb Company, Route 206 and  
Province Line Road, Princeton, New Jersey 08543 (US).  
**TATOSIAN, Daniel A.**; c/o Bristol-Myers Squibb Compa-  
ny, Route 206 and Province Line Road, Princeton, New Jer-  
sey 08543 (US). **TIRUCHERAI, Giridhar S.**; c/o Bris-  
tol-Myers Squibb Company, Route 206 and Province Line  
Road, Princeton, New Jersey 08543 (US). **TAO, Shiwei**; c/  
o Bristol-Myers Squibb Company, Route 206 and Province  
Line Road, Princeton, New Jersey 08543 (US).

(74) Agent: **CALVO, Paul A.** et al.; STERNE, KESSLER,  
GOLDSTEIN & FOX P.L.L.C., 1101 K Street NW, 10th  
Floor, Washington, District of Columbia 20005 (US).

(81) Designated States (unless otherwise indicated, for every  
kind of national protection available): AE, AG, AL, AM,  
AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ,  
CA, CH, CL, CN, CO, CR, CU, CV, CZ, DE, DJ, DK, DM,  
DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT,  
HN, HR, HU, ID, IL, IN, IQ, IR, IS, IT, JM, JO, JP, KE, KG,  
KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY,  
MA, MD, MG, MK, MN, MU, MW, MX, MY, MZ, NA,  
NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO,  
RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, ST, SV, SY, TH,  
TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, WS,  
ZA, ZM, ZW.

(84) Designated States (unless otherwise indicated, for every  
kind of regional protection available): ARIPO (BW, CV,  
GH, GM, KE, LR, LS, MW, MZ, NA, RW, SC, SD, SL, ST,  
SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ,  
RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ,  
DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT,  
LU, LV, MC, ME, MK, MT, NL, NO, PL, PT, RO, RS, SE,  
SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN,  
GQ, GW, KM, ML, MR, NE, SN, TD, TG).

Published:

- with international search report (Art. 21(3))
- before the expiration of the time limit for amending the  
claims and to be republished in the event of receipt of  
amendments (Rule 48.2(h))

(54) Title: LPA1 ANTAGONISTS FOR TREATING INTERSTITIAL LUNG DISEASE

(57) Abstract: This disclosure relates to methods of treating interstitial lung disease by administering an LPA<sub>1</sub> antagonist to the subject at one or more daily dosages lower than the standard daily dosage during a dose titration period of treatment then increasing the dosage to the standard daily dosage of the LPA<sub>1</sub> antagonist.

WO 2024/138185 A1